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Aim: To demonstrate the effect of local application of
Botox® in patients with amyotrophic lateral sclerosis (ALS),
following our 2002 institutional protocol of sialorrhea
treatment. Study Design: Clinical prospective. Material and
Method: Five patients with ALS assisted at Clinic of
Otolaryngology of AACD (Associação de Assistência à
Criança Deficiente). They were all submitted to local
application of Botox® in salivary glands and followed up
for a year. The protocol consisted of clinical questionnaire
about the inability of swallowing saliva and its repercussions
in quality of life. Patients were submitted to previous
odontological treatment, had intolerance to the adverse
effects of anti-cholinergic agents and had not used Botox®
for at least six months. The application was guided by
ultrasound and the doses were 30U in one point for
submandibular gland, and 20U in two points for each parotid
gland, after topic anesthetic with prilocaine. Results: Five
patients with ALS with sialorrhea, aged 45 to 59 years, were
submitted to Botox® salivary glands application. We
observed that the symptoms of sialorrhea changed
dramatically in four patients. Three patients stayed almost
four months without complaints with repercussion in quality
of life. No patient presented local or systemic effects with
local injection of Botox®.
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INTRODUCTION
The first report of saliva reduction with the use of
toxin botulinum was in cats by Dickson and Shevry in
1923¹. The use of botulinum toxin in salivary glands in
vivo was reported primary in patients with amyotrophic
lateral sclerosis (ALS) to block the action on cholinergic
autonomic fibers ¹.
In many neurological diseases, saliva stasis in the oral
cavity and oropharynx and/or extraoral leak of saliva indicate
neurogenic failure in coordination of tongue, palate and facial
muscles that act in the first stage of swallowing.
About 50% of the patients with ALS have significant
disorders in the control of saliva 2. Moreover, many other
hundreds of patients with neurological diseases present this
affection. These complaints collaborate to the social stigma
of the disease, leading to difficult social integration, stressing
depression and rehabilitation difficulties.
Among the treatment option, we can use drugs with
anti-cholinergic effects, anti-Parkinson drugs, surgical
treatment of salivary ducts or glands, radiotherapy in salivary
glands, and more recently, application of botulinum toxin
type A (Botox®) in salivary glands. Many patients present
intolerance to adverse events of the used drugs, or they
present very advanced and severe clinical conditions of the
neurological disease preventing surgical treatment, and
Botox® is the best alternative for treatment of sialorrhea.
However, in the literature, population samples are small and
heterogeneous, and doses, sites and application techniques
are variable.
OBJECTIVE
To demonstrate the results of the application of
Botox®, in a prospective study in a homogenous population
group, with standardized doses and techniques to reduce
saliva and symptoms resulting from inability to control it, as
well as the repercussions in quality of life.
MATERIAL AND METHOD
In the period between December 2002 and
December 2004, five patients with ALS with diagnosis for
2.8 years were consecutively selected in the Clinical
Otorhinolaryngology area of AACD (Associação de Assistên-
cia à Criança Deficiente) for application of Botox® in the
salivary glands. The follow up was performed on the 10th
day after application (first application), and subsequent
assessments were monthly for 12 months. The criteria used
for inclusion were:
1. Diagnosis of ALS for at least 2 years;
2. Clinical manifestations suggestive of sialorrhea:
accumulation of saliva in the oral cavity with continuous
need for elimination, oral leak of saliva, difficulty to speak
aggravated by accumulation of saliva in the oral cavity
and pharynx;
3. Intolerance in the use of anti-cholinergic drugs;
4. No use of botulinum toxin in other sites for the past 6
months;
5. Dental and periodontal treatment before the application
of Botox.
The questionnaire of results and quality of life was
used on the application day (pre-application) and on each
subsequent visit (post-application) and the responses were
given in three categories (never, occasionally, frequently).
The four questions were: need to eliminate saliva from the
mouth, participation in the family group during the meals,
embarrassment in public places because of sialorrhea,
physical contact on the face with family and close friends.
Treatment success was considered for the application and
quality of life when at least three responses that used to
be frequently before the application changed to never after
the application.
Application techniques
We performed topical anesthesia with prilocaine in
the parotid gland (PG) and submandibular gland (SG) region
thirty minutes before the application. The application of
Botox® in the PG region was made in two points: 10 U in
the angle between the posterior mandible angle and mastoid
process and 10U in the angle between the zigomatic process
and the ascending mandible process. In SG, we used
ultrasound-guided application and injected 30 U in each
gland in a central point.
Figure 1. Application of toxin botulinum in salivary glands - Points of
application of parotid gland (two points) and submandibular gland
(one point).
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RESULTS
In the period between December 2002 and
December 2004, five consecutive patients with ALS, aged
between 45 and 59 years, three female and two male, were
submitted to applications of Botox® to reduce the saliva.
We followed them up for 12 months. Four out of five patients
had significant improvement of symptoms and quality of
life, according to the criteria adopted for success, manifesting
the desire to inject it again. In one of them, there was no
reduction of saliva, but the patient presented the most severe
affections with complete inability of oral cavity and
oropharynx muscles. There were no systemic or local side
effects. In three patients, improvement was prolonged up
to the 4th month and in one patient the action of Botox®
was not detected anymore after the third month of
application.
DISCUSSION
Healthy subjects secrete from 1000 to 1500ml saliva
within 24 hours³. Many neurological diseases progress with
difficulties in the oral motor control. When the production
of saliva exceeds the subjects’ skill to transport it from the
mouth to the stomach, stasis, extraoral leak and aspiration
may take place, in addition to concomitant difficulty of
mastication and articulation. It is stigmatizing and the
prevalence in neurological diseases is high. Sialorrhea occurs
in about 50% of the patients with ALS and 20% of the victims
need continuous saliva elimination 2, which has prevalence
of about 70% in Parkinson disease 4, and between 10 and
80% in patients with cerebral palsy 5. The prevalence of
sialorrhea in these affections is high, with impairment of
social integration and difficulties to perform oral motor
activities during feeding and speech, with repercussions in
quality of life 6. We selected five patients with diagnosis of
ALS for at least two years.
Among the treatment options for sialorrhea, anti-
cholinergic drugs are the most widely used to reduce saliva,
but there may be systemic side effects (urinary retention,
loss of visual accommodation, headache, dry eyes), in addition
to development of drug tolerance 1.
Another more recent option is the use of Botox® in
PG and SG, despite the fact that botulinum toxin has a
limited action, which is not recommended for treatment of
chronic diseases, because of reapplications 3. In our opinion,
it is a little invasive procedure, very discreet and without
local or systemic adverse events, which means it is an
excellent treatment approach.
The literature brings a wide range of aspects about
the technique, dose, number of application points in the
glands, selection of salivary glands to be treated, criteria of
responses to treatment and side effects. Owing to the limited
number of studies that objectively explain all those elements
we would like to emphasize the importance of having a
treatment protocol with standardized technique and the dose
of applied botulinum toxin, plus the conduction of
quantitative and qualitative studies of salivary secretion. The
action of botulinum toxin in salivary glands inhibits the uptake
of acetylcholine in the neuroglandular junction, however,
differently from the neuromuscular action, other autonomic
stimuli are responsible for saliva secretion 7.
In the review of the literature, the glands normally
selected for Botox® application were isolated PG, or SG 5,
the combination of both PG and SG at the same time 7, or
still application in PG and if there is not the desired effect,
reapplication made in PG and SG 8. Given that PG and SG
are responsible for 80-90% of salivary secretion at rest, we
decided to include the two groups at the same application,
because the more the saliva were reduced, the better the
results.
In the first reports, there was no description of the
use of ultrasound to guide the application. More recent studies
reported the difficulty to identify the SG with palpation,
especially in children, and they reported that the accuracy
of the method could be improved by having direct view of
the needle under ultrasound guidance. The authors proposed
the puncture to be guided by USG in PG and SG 2. Some
authors advocated the administration of to PG in one single
point 1,6, two points7 or three points 8. Jongerius et al.. (2004)
radiologically demonstrated that the best distribution of the
substance in SG was the result of the application in two
points.
The injected dose in PG ranged from 5U6 to 72U² of
Botox®, and in the SG it ranged from 5U² to 50U5. We defined
the dose of 20U in PG (distributed in two points) and 30U
in SG (in one point).
We applied topical anesthesia for 30 minutes before
the application. The authors that reported application under
general anesthesia were Jongerius et al. (2004), because
they carried out the study in children with the application of
two points in the SG, with USG control, and probably accuracy
was hindered because the children did not collaborate in
the procedure.
Another controversial issue is the report of success
that is described in all studies, regardless of doses and
techniques. It may be justified by the subjectivity of the pre
and post-application controls. In most studies, the success
rate was given by subjective responses of the patient about
the control of sialorrhea, in others by the measurement of
dry cotton balls placed on the oral cavity before and after
the application 3 and the most objective criterion that we
observed was to analyze the results with the use of a quality
of life questionnaire and salivary gland scintigraphy 2. Our
criteria for subjective improvement was a four-question
questionnaire answered by the patients that showed the
reduction of extra-oral leak of saliva and social integration,
leading to the inference about reduction of salivary secretion
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and quality of life improvement. Four of the five patients
were success in their procedure. At the end of the follow up
period, four patients manifested they wanted to reapply
the injection, a situation that reflects the success of the
procedure. The minimum time of action of Botox® in clinical
responses was three months. The patient that did not show
success in treatment had very advanced condition of the
underlying disease, which was also reported by other authors
2. All authors have reported high success rates with Botox®
in salivary glands of most of the studied patients.
We did not observe increase in the incidence of den-
tal problems as a result of saliva reduction, despite the follow
up period of only 12 months, but we emphasized the
importance of careful dental hygiene and previous dental
treatment before the application, because the saliva becomes
thicker. Some authors reported that the reduction of salivary
flow could increase the incidence of dental decays 8. Among
the potential adverse events are xerostomia and worsening
of dysphagia owing to diffusion of the drug to mastication
muscles. We did not observe these adverse events in our
patients.
CONCLUSION
Application of 20U Botox® in parotid glands and 30U
in submandibular glands with the technique advocated in
the study was enough to reduce the saliva in patients and to
improve the quality of life of ALS patients, comprising an
alternative to the treatment of sialorrhea.
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